TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window
Ronald Koschny, Tom M. Ganten, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Armin Kolb, Wolfgang Stremmel, Henning WalczakVolume:
45
Year:
2007
Language:
english
Pages:
10
DOI:
10.1002/hep.21555
File:
PDF, 2.36 MB
english, 2007